These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

354 related items for PubMed ID: 9123739

  • 1. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer.
    Witjes WP, Schulman CC, Debruyne FM.
    Urology; 1997 Mar; 49(3A Suppl):65-9. PubMed ID: 9123739
    [Abstract] [Full Text] [Related]

  • 2. 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer.
    Schulman CC, Debruyne FM, Forster G, Selvaggi FP, Zlotta AR, Witjes WP.
    Eur Urol; 2000 Dec; 38(6):706-13. PubMed ID: 11111188
    [Abstract] [Full Text] [Related]

  • 3. Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109.
    Berglund RK, Tangen CM, Powell IJ, Lowe BA, Haas GP, Carroll PR, Canby-Hagino ED, deVere White R, Hemstreet GP, Crawford ED, Thompson IM, Klein EA.
    Urology; 2012 Mar; 79(3):633-7. PubMed ID: 22386416
    [Abstract] [Full Text] [Related]

  • 4. [Effect of complete androgen block before radical prostatectomy for cancer of the prostate].
    Gómez Veiga F, Lorenzo Patiño MJ, Díaz Bermúdez J, Duarte Novo J, Alvarez Castelo L, Chantada Abal V, Sánchez Rodríguez J, González Martín M.
    Arch Esp Urol; 1997 May; 50(4):355-63. PubMed ID: 9313044
    [Abstract] [Full Text] [Related]

  • 5. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
    Denham JW, Steigler A, Lamb DS, Joseph D, Turner S, Matthews J, Atkinson C, North J, Christie D, Spry NA, Tai KH, Wynne C, D'Este C.
    Lancet Oncol; 2011 May; 12(5):451-9. PubMed ID: 21440505
    [Abstract] [Full Text] [Related]

  • 6. Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer. Initial results of the Italian PROSIT study.
    Montironi R, Diamanti L, Santinelli A, Galetti-Prayer T, Zattoni F, Selvaggi FP, Pagano F, Bono AV.
    Pathol Res Pract; 1999 May; 195(4):201-8. PubMed ID: 10337657
    [Abstract] [Full Text] [Related]

  • 7. Neoadjuvant hormonal therapy prior to radical prostatectomy: the European experience.
    Debruyne FM, Witjes WP.
    Mol Urol; 2000 May; 4(3):251-6;discussion 257. PubMed ID: 11062381
    [Abstract] [Full Text] [Related]

  • 8. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects.
    Gleave ME, Goldenberg SL, Chin JL, Warner J, Saad F, Klotz LH, Jewett M, Kassabian V, Chetner M, Dupont C, Van Rensselaer S, Canadian Uro-Oncology Group.
    J Urol; 2001 Aug; 166(2):500-6; discussion 506-7. PubMed ID: 11458055
    [Abstract] [Full Text] [Related]

  • 9. Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year followup, Phase II Southwest Oncology Group Study 9109.
    Powell IJ, Tangen CM, Miller GJ, Lowe BA, Haas G, Carroll PR, Osswald MB, DeVERE WHITE R, Thompson IM, Crawford ED.
    J Urol; 2002 Nov; 168(5):2016-9. PubMed ID: 12394698
    [Abstract] [Full Text] [Related]

  • 10. Neoadjuvant androgen blockade prior to prostatectomy: a retrospective study and critical review.
    Schulman CC.
    Prostate Suppl; 1994 Nov; 5():9-14. PubMed ID: 7513532
    [Abstract] [Full Text] [Related]

  • 11. Neoadjuvant hormonal deprivation before radical prostatectomy.
    Schulman CC, Sassine AM.
    Clin Invest Med; 1993 Dec; 16(6):523-31. PubMed ID: 7516836
    [Abstract] [Full Text] [Related]

  • 12. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results.
    Fair WR, Cookson MS, Stroumbakis N, Cohen D, Aprikian AG, Wang Y, Russo P, Soloway SM, Sogani P, Sheinfeld J, Herr H, Dalgabni G, Begg CB, Heston WD, Reuter VE.
    Urology; 1997 Mar; 49(3A Suppl):46-55. PubMed ID: 9123736
    [Abstract] [Full Text] [Related]

  • 13. Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients.
    Leibowitz RL, Tucker SJ.
    Oncologist; 2001 Mar; 6(2):177-82. PubMed ID: 11306729
    [Abstract] [Full Text] [Related]

  • 14. PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancer. The Lupron Depot Neoadjuvant Study Group.
    McLeod DG, Johnson CF, Klein E, Peabody JO, Coffield S, Soloway M.
    Urology; 1997 Mar; 49(3A Suppl):70-3. PubMed ID: 9123740
    [Abstract] [Full Text] [Related]

  • 15. Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up.
    Gleave ME, La Bianca SE, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD.
    Urology; 2000 Aug 01; 56(2):289-94. PubMed ID: 10925096
    [Abstract] [Full Text] [Related]

  • 16. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
    Fair WR, Betancourt JE.
    Mol Urol; 2000 Aug 01; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
    [Abstract] [Full Text] [Related]

  • 17. [8-month neoadjuvant hormonal therapy before radical prostatectomy for high-risk prostate cancer].
    Tabata K, Satoh T, Matsumoto K, Fujita T, Irie A, Iwamura M, Yanagisawa N, Matsuda D, Muramoto M, Kadowaki K, Suyama K, Shoji K, Koh H, Kawakami T, Okayasu I, Egawa S, Baba S.
    Nihon Hinyokika Gakkai Zasshi; 2006 Jul 01; 97(5):712-8. PubMed ID: 16898594
    [Abstract] [Full Text] [Related]

  • 18. Stage T3 prostate cancer: a nonrandomized comparison between definitive irradiation and induction hormonal manipulation plus prostatectomy.
    Corn BW, Valicenti RK, Mulholland SG, Hyslop T, Gomella L.
    Urology; 1998 May 01; 51(5):782-7. PubMed ID: 9610592
    [Abstract] [Full Text] [Related]

  • 19. Effects of androgen deprivation prior to radical prostatectomy in 375 patients.
    Tunn UW, Acar O, Goldschmidt AJ.
    Urol Int; 1996 May 01; 56 Suppl 1():6-12. PubMed ID: 8776811
    [Abstract] [Full Text] [Related]

  • 20. Neoadjuvant hormonal therapy: the Canadian experience.
    Labrie F, Cusan L, Gomez JL, Diamond P, Suburu R, Lemay M, Tetu B, Fradet Y, Bélanger A, Candas B.
    Urology; 1997 Mar 01; 49(3A Suppl):56-64. PubMed ID: 9123738
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.